XENE Share Price Performance
US$0
-30.46 (-100.00%)
Price US$0
Fair ValueUS$58.58
Share Pricen/a
Seeking Alpha • Apr 22
Xenon Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
XENE Community Narratives
AN
Fair Value
·Fair Value US$58.58 6.7% undervalued intrinsic discount
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$55.4 1.3% undervalued intrinsic discount
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$100 45.3% undervalued intrinsic discount
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel based therapies for epilepsy, depression, bipolar disorder and pain. What are the underlying business or industry changes driving this perspective?Read more
AN
US$58.58
6.7% undervalued intrinsic discount
Fair Value
Profit Margin
14.77%
Future PE
358.46x
Price in 2029
US$71.48
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?Read more
AN
US$100
45.3% undervalued intrinsic discount
Fair Value
Profit Margin
2.02%
Future PE
680.12x
Price in 2029
US$122.1
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, mood disorders and pain. What are the underlying business or industry changes driving this perspective?Read more
AN
US$55.4
1.3% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
117.17x
Price in 2028
US$67.3
Trending Discussion
Recently Updated Narratives
AN
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
Fair Value: US$58.58 6.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Fair Value: US$100 45.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
Fair Value: US$55.4 1.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Xenon Pharmaceuticals Inc. Key Details
About XENE
- Founded
- 1996
- Employees
- 364
- CEO
- WebsiteView website
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
